Treatment of DME poses

Treatment of DME poses complex choices, strives to overcome limitations Diabetic macular edema remains a major concern despite the availability of technology for potentially earlier diagnosis and better options for treatment. The 2016 WHO Global Report on Diabetes...

Phase II Data Support Potential for Novel

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated...

Dexamethasone Implants

Dexamethasone Implants for Diabetic Macular Edema Diabetes is a raging epidemic in the United States, projected to impact nearly 600 million people within the next 20 years.1 Diabetic macular edema (DME) and diabetic retinopathy (DR) complications affect about 25% of...
On